The short answer: whether a Z-Pack works
A Z-Pack, which contains azithromycin, can work against some sinus infections caused by bacteria that are susceptible to it. It does not treat viral sinusitis, however, and many acute sinus illnesses do not require an antibiotic.
In US adults, azithromycin is also usually not the preferred empiric antibiotic for uncomplicated acute bacterial rhinosinusitis. Although the FDA labeling includes acute bacterial sinusitis caused by susceptible bacteria, current US outpatient guidance does not recommend macrolides such as azithromycin for empiric treatment because of high resistance among Streptococcus pneumoniae.
That creates an important distinction: a drug may have antibacterial activity and may have helped some people in clinical studies without being the best initial choice for a patient whose diagnosis has not yet been established. Whether azithromycin is appropriate depends on whether bacteria are likely to be causing the illness, which bacteria may be involved, and the prescribing guidance used in the relevant setting.
A Z-Pack should not be requested or used simply because sinus symptoms are uncomfortable or because azithromycin helped during a previous illness.
Why the cause of sinusitis changes the answer
Antibiotics act against bacteria. They do not treat viral sinusitis, so taking azithromycin for a viral illness does not address the cause of the symptoms. Antibiotic exposure can also cause adverse effects without providing a benefit when bacteria are not responsible.
Acute sinus symptoms can occur during or after a viral upper-respiratory illness. The presence of pressure, congestion, drainage, or facial discomfort does not by itself establish that an antibiotic is needed. The clinical course matters because some illnesses improve without antibacterial treatment, while a different pattern can make acute bacterial rhinosinusitis more likely.
Symptoms alone should not lead someone to take leftover azithromycin, use another person's prescription, or seek an antibiotic without clinical assessment. The same symptoms can arise in illnesses with different causes, and the appropriate treatment cannot be selected reliably from the medication's familiarity or from a single symptom.
Clinicians therefore consider how severe the illness is, how long it has continued without improvement, and whether it worsened after seeming to get better. Those patterns help determine whether an evaluation for acute bacterial rhinosinusitis is warranted, rather than making every episode of sinus discomfort an indication for antibiotics.
When clinicians suspect acute bacterial sinusitis
CDC adult outpatient guidance supports a diagnosis of acute bacterial rhinosinusitis when one of three clinical patterns is present:
- Symptoms are severe for more than 3-4 days.
- Symptoms persist for more than 10 days without improvement.
- Symptoms worsen after initial improvement following a viral upper-respiratory illness.
These patterns are used to support clinical judgment, not as an automatic prescription checklist. A person may need an examination and individualized assessment before a clinician decides whether bacterial sinusitis is likely and whether treatment is appropriate.
Colored mucus alone does not prove that the illness is bacterial. Drainage color should be considered alongside the overall course and severity rather than used as a reason to start azithromycin independently.
The distinction is especially important because antibiotics are intended for infections caused by susceptible bacteria. If the illness is viral, azithromycin will not treat its cause. If bacterial sinusitis is suspected, the clinician still has to select an antibiotic based on current guidance and the patient's circumstances; the presence of a bacterial pattern does not automatically make a Z-Pack the right choice.
Why azithromycin is usually not the first choice in the US
The FDA's US labeling includes acute bacterial sinusitis in adults caused by susceptible Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. This establishes a labeled use under the specified conditions, but it does not mean azithromycin is preferred for every adult with suspected bacterial sinusitis.
CDC outpatient guidance lists amoxicillin or amoxicillin-clavulanate as first-line therapy for acute bacterial rhinosinusitis. It states that macrolides such as azithromycin are not recommended for empiric therapy because of high Streptococcus pneumoniae resistance.
An antibiotic can appear effective in some trials and still not be the usual initial choice in current US practice. Prescribing guidance considers whether the drug is likely to cover the bacteria commonly involved in an illness, not only whether the drug has shown activity under study conditions.
A clinician selects treatment after considering the diagnosis and the patient's circumstances. The presence of a sinus infection does not make a familiar Z-Pack interchangeable with the first-line options listed in US outpatient guidance, and a patient should not substitute azithromycin based on an old prescription or a prior experience.
What studies of azithromycin for sinusitis show
A 2025 systematic review and meta-analysis combined 14 randomized trials involving 4,201 participants. Across those studies, the pooled clinical cure rate with azithromycin was 70.86%, and the pooled adverse-event rate was 14.33%.
These results show that azithromycin produced clinical cures in the studied populations. They do not predict whether it will work for one particular person. The trials included heterogeneous populations, sinusitis types, regimens, comparators, and diagnostic approaches, and the review reported meaningful heterogeneity. The available information was not sufficient for definitive conclusions about efficacy across all sinusitis settings.
The pooled findings also did not establish that azithromycin was superior to penicillins or to the clarithromycin family in subgroup comparisons. A treatment that performs reasonably in a group of trials is not automatically the preferred empiric treatment in current practice.
The apparent tension between the studies and US guidance reflects different questions. Clinical trials ask how participants in selected study settings responded to particular regimens. Prescribing guidance also weighs current resistance concerns, including high resistance among Streptococcus pneumoniae to macrolides. Positive trial results can support the conclusion that azithromycin may work in some circumstances without supporting routine first-line use for current US outpatient treatment.
Z-Pack dosing versus the labeled sinusitis regimen
'Z-Pack' is a familiar packaging and regimen term, commonly associated with a five-day azithromycin schedule. That schedule should not automatically be treated as the FDA-labeled adult regimen for acute bacterial sinusitis.
US ZITHROMAX labeling lists an adult acute bacterial sinusitis regimen of 500 mg once daily for three days. This is regulatory information, not individualized dosing advice. It differs from the familiar five-day Z-Pack schedule.
The difference matters because the number of tablets in a familiar package does not determine whether azithromycin is appropriate for a particular diagnosis, nor does it establish that the package's usual schedule applies to sinusitis. A person should not use leftover tablets, change a prescribed schedule, or treat the labeled regimen as permission to self-diagnose bacterial sinusitis.
If a clinician prescribes azithromycin, the prescription directions should be followed rather than replaced with a remembered Z-Pack schedule. If the directions are unclear or the medication on hand does not match the current prescription, the prescriber or pharmacist can clarify how it should be used.
Safety, treatment follow-up, and responsible antibiotic use
Azithromycin labeling identifies diarrhea, nausea, abdominal pain, and vomiting among common adverse reactions. It also warns that QT prolongation and potentially fatal cardiac rhythm disturbances can occur, with greater concern for people who have relevant cardiac risks or take certain rhythm-affecting drugs. This is one reason an antibiotic should be selected and used with clinical oversight rather than borrowed or reused.
Follow the prescriber's directions if azithromycin is prescribed. Contact a clinician if symptoms worsen, fail to improve as expected, or adverse effects occur. There is no single response deadline that applies to every person, so follow-up depends on the illness and the treatment plan.
Unnecessary antibiotic exposure can contribute to antibiotic resistance and provides no benefit when sinus symptoms are caused by a virus. Leftover medication may also be an incomplete course, may have been prescribed for a different illness, or may not match current treatment guidance. Sharing or saving it for later can delay appropriate assessment.
The responsible approach is to have persistent, severe, or worsening sinus symptoms evaluated, use antibiotics only when a clinician determines they are appropriate, and avoid treating a familiar Z-Pack as a general remedy for sinus symptoms.